Safety, Effectiveness and Immunogenicity of heterologous mRNA-1273 Boost after Prime with Ad26.COV2.S among Healthcare Workers in South Africa: the single-arm, open-label, Phase 3 SHERPA Study
Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, Azwidhwi Takalani, Kubashni Woeber, Annie Bodenstein, Phumeza Jonas, Imke Engelbrecht, Waasila Jassat, Harry Moultrie, Debbie Bradshaw, Ishen Seocharan, Jackline Odhiambo, Kentse Khuto, Simone I. Richardson, Millicent A. Omondi, Rofhiwa Nesamari, Roanne S. Keeton, Catherine Riou, Thandeka Moyo-Gwete, Craig Innes, Zwelethu Zwane, Kathy Mngadi, William Brumskine, Nivashnee Naicker, Disebo Potloane, Sharlaa Badal-Faesen, Steve Innes, Shaun Barnabas, Johan Lombaard, Katherine Gill, Maphoshane Nchabeleng, Elizma Snyman, Friedrich Petrick, Elizabeth Spooner, Logashvari Naidoo, Dishiki Kalonji, Vimla Naicker, Nishanta Singh, Rebone Maboa, Pamela Mda, Daniel Malan, Anusha Nana, Mookho Malahleha, Philip Kotze, Jon J. Allagappen, Andreas H. Diacon, Gertruida M. Kruger, Faeezah Patel, Penny L. Moore, Wendy A. Burgers, Kate Anteyi, Brett Leav, Linda-Gail Bekker, Glenda E Gray, Ameena Goga, the SHERPA study team
medRxiv 2024.06.07.24306760; doi: https://doi.org/10.1101/2024.06.07.24306760
